title: [The effects of olmesartan on ambulatory blood pressures and blood pressure variability in patients with mild to moderate essential hypertension].
abstract: OBJECTIVE
  To evaluate the effect of olmesartan medoxomil tablets (olmesartan) in comparison with Olmetec on 24 h ambulatory blood pressure (ABPM) and blood pressure variability (BPV) in patients with mild to moderate hypertension.
  
  
  METHODS
  A randomized, double-blind, double-mimic controlled trial was performed.Forty-eight patients with mild to moderate essential hypertension were randomly into treatment group (olmesartan) and control group (Olmetec) for eight weeks. The ABPM was taken before and at the end of the trial.
  
  
  RESULTS
  After eight weeks, treatment with olmesartan induced a significant reduction in ABPM in patients [(9 ± 3)/(11 ± 3) mmHg(1 mmHg = 0.133 kPa)], which is similar with the reduction by Olmetec [(9 ± 4)/(9 ± 5) mmHg], P > 0.05. This situation holds for BPV with the standard deviations of 24 h, systolic blood pressure/diastolic blood pressure of pre-treatment and pro-treatment were (10 ± 2)/(11 ± 3) mmHg vs (10 ± 3)/(12 ± 2) mmHg in olmesartan group, and (10 ± 3)/(11 ± 3) mmHg vs (12 ± 3)/(12 ± 4) mmHg in Olmetec group. (3) There is no difference in the rate of adverse event between olmesartan (10.42%) and Olmetec (8.33%) treatment (P > 0.05).
  
  
  CONCLUSIONS
  Similar to Olmetec, treatment with olmesartan once daily can significantly reduce ABPM in patients with mild to moderate essential hypertension.
authors.forename: Jing
authors.initials: J
authors.lastname: Li
authors.forename: Tingli
authors.initials: T
authors.lastname: Qin
authors.forename: Hong
authors.initials: H
authors.lastname: Jiang
authors.forename: Hao
authors.initials: H
authors.lastname: Wang
authors.affiliation: Department of Cardiology, China-Japan Friendship Hospital, Beijing 100029, China. Email: keyuannan6666@aliyun.com.
authors.forename: Yuannan
authors.initials: Y
authors.lastname: Ke
mesh_terms: D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001794:Blood Pressure; D018660:Blood Pressure Monitoring, Ambulatory; D004311:Double-Blind Method; D000075222:Essential Hypertension; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D007093:Imidazoles / Q000627:therapeutic use*; D000068557:Olmesartan Medoxomil; D013777:Tetrazoles / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000959:Antihypertensive Agents; D007093:Imidazoles; D013777:Tetrazoles; D000068557:Olmesartan Medoxomil